Xinxiang Tuoxin Pharmaceutical Co.Ltd.
Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates in China. It offers nucleoside (acid) products, such as pyrimidine series, purine series, and nucleotide series; nucleoside series, including citicoline sodium, ribavirin, inosine, acyclovir, azithromycin, cytosine, 5-fluorocytosine, cytidin… Read more
Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) - Net Assets
Latest net assets as of June 2025: CN¥1.53 Billion CNY
Based on the latest financial reports, Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) has net assets worth CN¥1.53 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.71 Billion) and total liabilities (CN¥172.99 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.53 Billion |
| % of Total Assets | 89.87% |
| Annual Growth Rate | 32.28% |
| 5-Year Change | 216.28% |
| 10-Year Change | N/A |
| Growth Volatility | 44.12 |
Xinxiang Tuoxin Pharmaceutical Co.Ltd. - Net Assets Trend (2019–2024)
This chart illustrates how Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Xinxiang Tuoxin Pharmaceutical Co.Ltd. (2019–2024)
The table below shows the annual net assets of Xinxiang Tuoxin Pharmaceutical Co.Ltd. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.55 Billion | -3.17% |
| 2023-12-31 | CN¥1.60 Billion | +16.49% |
| 2022-12-31 | CN¥1.38 Billion | +25.43% |
| 2021-12-31 | CN¥1.10 Billion | +123.55% |
| 2020-12-31 | CN¥490.87 Million | +28.13% |
| 2019-12-31 | CN¥383.11 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 276.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥737.43 Million | 47.50% |
| Other Components | CN¥815.09 Million | 52.50% |
| Total Equity | CN¥1.55 Billion | 100.00% |
Xinxiang Tuoxin Pharmaceutical Co.Ltd. Competitors by Market Cap
The table below lists competitors of Xinxiang Tuoxin Pharmaceutical Co.Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nam Viet Corp
VN:ANV
|
$223.17 Million |
|
Newsmax, Inc.
NYSE:NMAX
|
$223.20 Million |
|
United Insurance Holdings Corp
F:0UI
|
$223.21 Million |
|
Sinocat Environmental Technology Co Ltd
SHG:688737
|
$223.23 Million |
|
Wuxi Jinyang New Materials Co. Ltd. A
SHE:301210
|
$223.13 Million |
|
Shenzhen Keybridge Communications Co Ltd
SHE:002316
|
$223.09 Million |
|
Shanghai Shentong Metro Co Ltd
SHG:600834
|
$223.08 Million |
|
Chongqing Pharscin Pharmaceutical Co Ltd
SHE:002907
|
$223.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,603,271,869 to 1,552,520,060, a change of -50,751,808 (-3.2%).
- Net loss of 19,884,869 reduced equity.
- Dividend payments of 31,636,125 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-19.88 Million | -1.28% |
| Dividends Paid | CN¥31.64 Million | -2.04% |
| Other Changes | CN¥769.19K | +0.05% |
| Total Change | CN¥- | -3.17% |
Book Value vs Market Value Analysis
This analysis compares Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.34x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 7.08x to 2.34x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥4.05 | CN¥28.70 | x |
| 2020-12-31 | CN¥5.19 | CN¥28.70 | x |
| 2021-12-31 | CN¥8.71 | CN¥28.70 | x |
| 2022-12-31 | CN¥10.92 | CN¥28.70 | x |
| 2023-12-31 | CN¥12.67 | CN¥28.70 | x |
| 2024-12-31 | CN¥12.27 | CN¥28.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Xinxiang Tuoxin Pharmaceutical Co.Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.28%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.72%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 1.13x
- Recent ROE (-1.28%) is below the historical average (13.28%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 15.99% | 15.87% | 0.52x | 1.93x | CN¥22.94 Million |
| 2020 | 22.98% | 21.37% | 0.56x | 1.93x | CN¥63.71 Million |
| 2021 | 5.99% | 13.08% | 0.36x | 1.27x | CN¥-44.02 Million |
| 2022 | 20.82% | 36.51% | 0.43x | 1.34x | CN¥148.90 Million |
| 2023 | 15.16% | 29.09% | 0.45x | 1.15x | CN¥82.75 Million |
| 2024 | -1.28% | -4.72% | 0.24x | 1.13x | CN¥-175.14 Million |
Industry Comparison
This section compares Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) | CN¥1.53 Billion | 15.99% | 0.11x | $223.17 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |